Merck return of rights pushes Cardiome to weigh vernakalant options
This article was originally published in Scrip
Executive Summary
Few questions were asked - and even fewer answered - when Cardiome Pharma executives spoke with analysts and reporters on 26 September about Merck returning the global marketing and development rights for oral and intravenous formulations of the atrial fibrillation (AF) drug vernakalant to the Canadian company.